Anna Nichols
Dermatology · Plattsburgh, NYNPI 1518227594
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,413 of the $14,411 with a category attached, or 72.3%. Boehringer Ingelheim accounts for 66.7% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $9,452, more than ten times the $171 reported in 2019.
Across 14 payments — averaging $1029.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$10K
- Boehringer Ingelheim International GmbH$5K
- Pfizer$122
- Novartis$72
Across 132 payments — averaging $5275.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$307K
- Regeneron$134K
- AbbVie$88K
- Boehringer Ingelheim$82K
- Kiniksa Pharmaceuticals, Ltd.$67K
- Pfizer$13K
- plus $6K from 2 others
What the payments were for
- Consulting fees$3,65125%
- Speaking & faculty fees$10,41372%
- Food & beverage$3472%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $9,605 |
| Boehringer Ingelheim International GmbH | 5 | $4,612 |
| Pfizer | 1 | $122 |
| Novartis | 3 | $72 |
How this compares
$14,411 in reported general payments places this provider in the 80th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 130 | $8,490 |
| Ketoconazole | 86 | $1,238 |
| Tacrolimus | 11 | $782 |
| Metronidazole | 14 | $539 |
| Clobetasol Propionate | 19 | $433 |
| Triamcinolone Acetonide | 52 | $294 |
| Mupirocin | 19 | $139 |
| Hydrocortisone | 23 | $130 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Plattsburgh
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.